Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Mayo Clinic · NCT04232566
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 30–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 60
- US sites recruiting
- 1
- Study start
- February 20, 2022
- Record last updated
- January 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
Being studied: Bariatric surgery
Conditions: Obesity, Morbid; NASH - Nonalcoholic Steatohepatitis; Chronic Inflammation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Undergoing gastric bypass surgery
- Confirmed AUROC F=0 or F>2 liver fibrosis
- Age 30-70 years
- BMI greater than 40 kg/m2
- Negative pregnancy test (female only)
- Lab Values: Normal TSH
Exclusion Criteria
- Autoimmune diseases
- Hepatitis B or C positive
- Heavy alcohol use
- Active smoking history
- Active cancer history
- History of asthma
- History of COPD
- Taking Plavix or Coumadin
- Blood donation within past 2 months
- Glucocorticoid Therapy
- Taking antihistamine on regular basis
Recruiting US locations
Mayo Clinic in Arizona
Scottsdale, AZ 85259
Site contact: Stewart Keegan · 480-301-4164 · stewart.keegan@mayo.edu
Study contacts (from the official record)
- Keegan M Stewart · 480-301-4164 · stewart.keegan@mayo.edu
Similar studies in Arizona
All weight loss studies in Arizona →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Chandler, AZ + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Chandler, AZ + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Scottsdale, AZ + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Sun City, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75